Video

Dr. Bekaii-Saab on the Impact of Next-Generation Sequencing in mCRC

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

A couple of years ago, physicians would have likely said that genomic sequencing should be reserved for a select group of patients, says Bekaii-Saab. Now, every patient should get microsatellite instability (MSI) testing. Additionally, physicians now know that MSI is a surrogate biomarker for tumor mutational burden (TMB). All of these genomic platforms are showing that TMB has meaningful cutoffs, says Bekaii-Saab. Patients with high and potentially intermediate cutoffs respond to immunotherapy agents, whereas patients with low cutoffs do not. Now, TMB is being used to identify whether a patient should receive a PD-1 inhibitor or not.

For patients with KRAS and RAS mutations, testing is still limited, notes Bekaii-Saab, though identifying a BRAF mutation can help steer physicians toward the proper treatment. Physicians know that these patients have a worse prognosis with FOLFOX or FOLFOXIRI. Therefore, bevacizumab (Avastin) may be more suitable in the frontline setting.

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD